The utility of -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature

Investor logo

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.
Authors

SIMONSEN Anja Hviid KUIPERIJ Bea EL-AGNAF Omar Mukhtar Ali ENGELBORGHS Sebastian HERUKKA Sanna-Kaisa PARNETTI Lucilla REKTOROVÁ Irena VANMECHELEN Eugeen KAPAKI Elisabeth VERBEEK Marcel MOLLENHAUER Brit

Year of publication 2016
Type Article in Periodical
Magazine / Source BIOMARKERS IN MEDICINE
MU Faculty or unit

Central European Institute of Technology

Citation
Web http://www.futuremedicine.com/doi/10.2217/BMM.14.105
Doi http://dx.doi.org/10.2217/BMM.14.105
Field Neurology, neurosurgery, neurosciences
Keywords alpha-synuclein; biomarker; CSF; diagnosis; ELISA; Parkinson's disease
Attached files
Description The discovery of -synuclein (-syn) as a major component of Lewy bodies, neuropathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies and of glial inclusions in multiple system atrophy initiated the investigation of -syn as a biomarker in cerebrospinal fluid (CSF). Due to the involvement of the periphery in PD the quantification of -syn in peripheral fluids such as serum, plasma and saliva has been investigated as well. We review how the development of multiple assays for the quantification of -syn has yielded novel insights into the variety of -syn species present in the different fluids; the optimal preanalytical conditions required for robust quantification and the potential clinical value of -syn as biomarker. We also suggest future approaches to use of CSF -syn in neurodegenerative diseases.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.